JP4455321B2 - カルバメート置換ピラゾロピリジン類 - Google Patents
カルバメート置換ピラゾロピリジン類 Download PDFInfo
- Publication number
- JP4455321B2 JP4455321B2 JP2004503467A JP2004503467A JP4455321B2 JP 4455321 B2 JP4455321 B2 JP 4455321B2 JP 2004503467 A JP2004503467 A JP 2004503467A JP 2004503467 A JP2004503467 A JP 2004503467A JP 4455321 B2 JP4455321 B2 JP 4455321B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- fluorobenzyl
- pyrazolo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 *c(nc(-c1n[n](Cc(cccc2)c2F)c2c1cccn2)nc1N)c1I Chemical compound *c(nc(-c1n[n](Cc(cccc2)c2F)c2c1cccn2)nc1N)c1I 0.000 description 1
- LQCFFAGUCURQEC-UHFFFAOYSA-N NC(c1n[n](Cc2ccccc2F)c2c1cccn2)=N Chemical compound NC(c1n[n](Cc2ccccc2F)c2c1cccn2)=N LQCFFAGUCURQEC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
R1は、−NR3C(=O)OR4であり、
R2は、水素またはNH2であり、
R3は、水素または(C1−C4)−アルキルであり、
R4は(C1−C6)−アルキルである、
の化合物、並びにそれらの塩、異性体および水和物に関する。
R1が−NR3C(=O)OR4であり、
R2が水素またはNH2であり、
R3が(C1−C4)−アルキルであり、
R4が(C1−C4)−アルキルである、
式(I)の化合物、並びにそれらの塩、異性体および水和物である。
R1が−NR3C(=O)OR4であり、
R2がNH2であり、
R3がメチルまたはエチルであり、
R4がメチル、エチルまたはイソプロピルである、
式(I)の化合物、並びにそれらの塩、異性体および水和物である。
本発明の化合物は、さらに、生じ得るそれらの水和物の形態でもあり得る。
ハロゲンは、本発明のためには、フッ素、塩素、臭素およびヨウ素である。
[A]式(Ia)
の化合物を、式(II)
R3−X1(II)
式中、R3は、上記定義の通りであり、そして、
X1は、脱離基、例えば、ハロゲン、好ましくはヨウ素、またはメシラートなど、である、
の化合物と、適するならば有機溶媒中、冷却しながら反応させ、式(I)の化合物を得る。
[C]式(V)
の化合物と、適するならば有機溶媒中、加熱しながら反応させ、式(Ib)
の化合物を得る。
本発明の式(I)の化合物は、血管弛緩および血小板凝集の阻害をもたらし、血圧の低下および冠状動脈血流の増加を導く。これらの作用は、可溶性グアニル酸シクラーゼの直接刺激およびcGMPの細胞内増加によって媒介される。さらに、本発明の式(I)の化合物は、cGMPレベルを増大させる物質、例えば、EDRF(内皮由来弛緩因子)、NO供与体、プロトポルフィリンIX、アラキドン酸またはフェニルヒドラジン誘導体の作用を増強する。
本発明の式(I)の化合物は、卒中、脳虚血および頭蓋脳外傷のような脳梗塞の後遺症の予防および制御にも好適である。それらは、同様に、疼痛状態の制御にも用いることができる。
加えて、本発明の式(I)の化合物は、抗炎症作用を有し、従って、抗炎症物質として用いることもできる。
本発明のための有機硝酸塩およびNO供与体は、一般的に、NOまたはNO種の放出を介してそれらの治療効果を発揮する物質である。例えば、そして好ましくは、ニトロプルシドナトリウム、ニトログリセリン、イソソルビドジニトレート、イソソルビドモノニトレート、モルシドミンおよびSIN-1が挙げられる。
インビトロにおける血管弛緩作用
首の後に一撃を加えてウサギを気絶させ、放血させる。大動脈を取り出し、付着組織を除去し、1.5mm幅の輪に分割し、これを、以下の組成(mM):NaCl:119;KCl:4.8;CaCl2x2H2O:1;MgSO4x7H2O:1.4;KH2PO4:1.2;NaHCO3:25;グルコース:10を有する、37℃のカルボゲン(carbogen)ガス処理した Krebs-Henseleit 溶液を含有する器官浴5mL中で、1つずつ緊張状態におく。収縮力を Statham UC2 のセルで検出し、A/D変換器 (DAS-1802 HC, Keithley 器具s Munich) で増幅し、数値化し、並行してチャートレコーダーに記録する。フェニレフリンを、増大する濃度で漸増的に浴に添加することによって、収縮を発生させる。数回の対照サイクル後に、被験物質を、それぞれの後続ランにおいて、各場合に増加する用量で試験し、収縮の高さを、直前のランで到達した収縮の高さと比較する。対照値の高さを50%減少させるのに必要な濃度(IC50)を、これから算出する。標準適用容量は5μlであり、浴溶液中のDMSO含量は0.1%に相当する。
実施例1の化合物のIC50は670nMであり、実施例8の化合物の対応値は500nMである。
体重3−5kgの成体のオスのチンチラウサギを、配達後数日、単独で飼われることに順応させる。それらは自由に水に接近でき、一日に2時間、飼料を摂ることができる。動物は、10/14時間の昼/夜リズム(8時から点灯)で飼われ、室温は22−24℃である。
経口投与のために、試験物質を6:10:9.69グリセロール:水:ポリエチレングリコール混合物に溶解し、胃管栄養法により1ml/kgの量で投与する。
実施例8の化合物の経口投与での最低有効用量は、0.03mg/kg(0.2mg/kg i.v.ニトロプルシドナトリウムSNPの同時投与を伴う)である。
被験物質を液剤として動物(例えば、マウス、ラット、イヌ)に静脈投与し、経口投与は、胃管栄養による液剤または懸濁剤として行う。物質投与後、指定時間に動物から血液を採取し、ヘパリン処理し、遠心分離によりそれらから血漿を得る。該血漿中の物質をLC/MS/MSにより分析的に定量する。かくして判明した血漿濃度/時間経過を、有効な薬物動態学用コンピュータープログラムを利用する薬物動態学的パラメータの算出に使用する。
AUC水準(stand)(0.3mg/kg)=0.326[kg*h/L]
AUC水準(1.0mg/kg)=0.548[kg*h/L]
代謝に重要であるP−450イソ酵素を阻害する潜在能力を、96ウェル形式で自動的に試験する。これには2つの異なるアッセイを使用する。
蛍光代謝物の形成をベースとするアッセイでは、組換え酵素(例えば、CYP1A2、2C8、2C9、2C19、2D6または3A4)および一般にフルオレセインまたはクマリンの部分構造を含有する基質を用いる。各場合に、1つの基質濃度と8つの潜在的阻害物質の濃度を使用する。特定の組換えCYP酵素とのインキュベーションの後、蛍光読み取り機を使用して、対照(阻害物質なし)と比較した蛍光代謝物の程度を測定し、IC50を算出する [Anal. Biochem. 248, 188 (1997)]。
チトクロムP450酵素の阻害に関して本発明の物質の副作用の可能性を調べるために、初代ヒト肝細胞を、細胞濃度2.5X105細胞、2層のコラーゲンの間で、24ウェルのマイクロタイタープレート中、37℃、5%CO2で、8日間培養する。細胞培養培地は、毎日交換する。
経口投与に適するのは、有効成分を迅速かつ/または修飾されたやり方で送達する既知の投与形であり、例えば、錠剤(非被覆および被覆錠剤、例えば、腸溶性被覆を施された錠剤、またはフィルム被覆錠剤)、カプセル剤、糖衣錠剤、顆粒剤、ペレット剤、粉末剤、乳剤、懸濁剤、液剤およびエアゾル剤である。
詳述した医薬製剤は、本発明の式(I)の化合物とは別に、他の有効医薬成分も含有できる。
T1 E1:トルエン/酢酸エチル(1:1)
T1 EtOH1:トルエン/エタノール(1:1)
C1 E1:シクロヘキサン/酢酸エチル(1:1)
C1 E2:シクロヘキサン/酢酸エチル(1:2)
方法1(LCMS)
器具:Micromass Platform LCZ, HP1100;カラム:Symmetry C18、50mmx2.1mm、3.5μm;溶離剤A:アセトニトリル+0.1%蟻酸、溶離剤B:水+0.1%蟻酸;勾配:0.0分10%A→4.0分90%A→6.0分90%A;オーブン:40℃;流速:0.5ml/分;UV検出:208−400nm。
器具:Waters Alliance 2790 LC;カラム:Symmetry C18、50mmx2.1mm、3.5μm;溶離剤A:水+0.1%蟻酸、溶離剤B:アセトニトリル+0.1%蟻酸;勾配:0.0分5%B→5.0分10%B→6.0分10%B;温度:50℃;流速:1.0ml/分;UV検出:210nm。
器具:DAD を有する HP 1100;カラム:Kromasil RP-18、60mmx2mm、3.5μm;溶離剤:A=HClO45ml/H2O1l、B=ACN;勾配:0分2%B、0.5分2%B、4.5分90%B、6.5分90%B;流速:0.75ml/分;温度:30℃;検出UV210nm。
カラム:YMC gel;溶離剤:アセトニトリル/水(勾配);流速:50ml/分;温度:25℃;検出UV210nm。
実施例1A
エチル5−アミノ−1−(2−フルオロベンジル)ピラゾール−3−カルボキシラート
エチル1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−カルボキシラート
融点85℃
Rf(SiO2、T1 E1):0.83
1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−カルボキサミド
Rf(SiO2、T1 E1):0.33
3−シアノ−1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン
収量:33.7g(理論値の100%)
融点:81℃
Rf(SiO2、T1 E1):0.74
メチル1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−カルボキシイミダート
1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−カルボキサミジン
収量27.5g(2工程の理論値の76.4%)
m.p.:86℃
Rf(SiO2、T1 EtOH1):0.08
2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−[(E)フェニルジアゼニル]−4,6−ピリミジンジアミン
2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−4,5,6−ピリミジントリアミン三塩酸塩
メチルシアノメチル(メチル)カルバメート
ナトリウム(E)−2−シアノ−2−[(メトキシカルボニル)(メチル)アミノ]エタノラート
収量:1.05g(理論値の76%)
HPLC(方法4):Rt=1.35分
1H-NMR (200 MHz, DMSO-d6): δ = 2.90 (d, 1H), 3.35 (s, 3H), 3.47 (s, 3H).
実施例1
メチル4−アミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニル(メチル)カルバメート
収量:20.2mg(理論値の2%)
LC/MS(方法2):Rt=3.01分
MS(EI):m/z=408(M+H)+
1H-NMR (300 MHz, DMSO-d6): δ = 3.09 (s, 3H), 3.29 (s, 3H), 5.83 (s, 2H), 7.09-7.42 (m, 5H), 8.20 (s, 1H), 8.64 (dd, 1H). 8.94 (dd, 1H), 9.27 (br. s, 2H).
エチル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニルカルバメート
収量:56.2mg(理論値の43%)
LC/MS(方法1):Rt=2.66分
MS(EI):m/z=423(M+H)+
1H-NMR (300 MHz, DMSO-d6): δ = 1.17-1.33 (m, 3H), 3.97-4.14 (m, 2H), 5.80 (s, 2H), 6.14 (br. s, 4H), 7.07-7.17 (m, 2H), 7.22 (t, 1H). 7.29-7.40 (m, 2H), 7.97 (br. s, 1H), 8.60 (d, 1H), 9.07 (d, 1H).
イソプロピル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニルカルバメート
収量:165mg(理論値の88%)
LC/MS(方法1):Rt=2.84分
MS(EI):m/z=437(M+H)+
1H-NMR (300 MHz, DMSO-d6): δ = 1.26 (d, 6H), 4.82 (quin., 1H), 5.92 (s, 2H), 7.07-7.20 (m, 2H), 7.25 (t, 1H). 7.31-7.43 (m, 2H), 7.47-7.57 (m, 1H), 8.16 (br. s, 1H), 8.74 (dd, 1H), 8.98 (dd, 1H).
ネオペンチル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニルカルバメート
収量:54mg(理論値の41%)
LC/MS(方法1):Rt=3.10分
MS(EI):m/z=465(M+H)+
1H-NMR (400 MHz, DMSO-d6): δ = 0.95 (br. s, 9H), 3.74 (s, 2H), 5.79 (s, 2H), 6.10 (br. s, 4H), 7.08-7.17 (m, 2H), 7.22 (t, 1H), 7.29-7.39 (m, 2H), 8.00 (br. s, 1H), 8.60 (dd, 1H), 9.06 (dd, 1H).
メチル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニルカルバメート
収量:32.6g(理論値の92%)
LC/MS(方法1):Rt=2.61分
MS(EI):m/z=409(M+H)+
1H-NMR (400 MHz, DMSO-d6): δ = 3.61 (s, 3H), 5.80 (s, 2H), 6.19 (br. s, 4H), 7.08-7.16 (m, 2H), 7.22 (t, 1H), 7.28-7.39 (m, 2H), 7.99 (br. s, 1H), 8.60 (dd, 1H), 9.05 (dd, 1H).
エチル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニル(メチル)カルバメート
収量:32mg(理論値の58%)
LC/MS(方法2):Rt=2.91分
MS(EI):m/z=437(M+H)+
1H-NMR (200 MHz, DMSO-d6): δ = 1.08 (t, 3H), 2.99 (s, 3H), 2.93-4.11 (m, 2H), 5.79 (s, 2H), 6.35 (br. s, 4H), 7.06-7.14 (m, 2H), 7.16-7.28 (m, 1H), 7.28-7.32 (m, 2H), 8.59 (dd, 1H), 9.06 (dd, 1H).
イソプロピル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニル(メチル)カルバメート
収量:32mg(理論値の41%)
LC/MS(方法1):Rt=2.97分
MS(EI):m/z=451(M+H)+
1H-NMR (300 MHz, DMSO-d6): δ = 1.09 (d, 6H), 2.98 (s, 3H), 4.80 (quin., 1H), 5.79 (s, 2H), 6.31 (br. s, 4H), 7.05-7.16 (m, 2H), 7.22 (t, 1H), 7.28-7.40 (m, 2H), 8.59 (dd, 1H), 9.07 (dd, 1H).
メチル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニル(メチル)カルバメート
収量:93mg(理論値の29%)
実施例5由来のメチル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニルカルバメート20.0g(49.0mmol)を、テトラヒドロフラン257mlに溶解し、0℃に冷却する。リチウムビス(トリメチルシリル)アミド53.9ml(1Mテトラヒドロフラン溶液で49.0mmol)を、15分間かけて滴下して添加する。0℃で20分間撹拌した後、ヨードメタン6.95g(53.9mmol)を添加する。1時間後、混合物を室温に温まらせ、飽和水性塩化アンモニウム溶液の添加により反応を停止させる。相を分離する。酢酸エチルおよびジクロロメタンで水相を数回抽出する。合わせた有機相を真空で濃縮する。かくして得られる残渣を、ジクロロメタンとテトラヒドロフランの混合物(1:1)に懸濁する。不溶性結晶を吸引濾過し、メタノールに溶かす。混合物を1時間還流する。冷却後、析出してくる沈殿を濾取する。かくして得られた赤色固体を、ジオキサンとジクロロメタンの混合物(1:1)100mlに懸濁し、沸騰させながら、透明な溶液が形成されるまでメタノール20mlを添加する。活性炭を添加し、混合物を短時間沸騰させ、珪藻土を通して熱いまま濾過する。かくして得られる溶液を乾燥するまで蒸発させる。メタノールに溶かした後の懸濁液を室温で1時間撹拌する。白色結晶を吸引濾過する。
収量:14.9g(理論値の72%)
LC/MS(方法3):Rt=1.85分
MS(EI):m/z=423(M+H)+
1H-NMR (200 MHz, DMSO-d6): δ = 3.01 (s, 3H), 3.57 (s, 3H), 5.92 (s, 2H), 7.05.7.17 (m, 2H), 7.18-7.46 (m, 3H), 7.47-7.61 (m, 2H), 7.59-7.97 (m, 2H), 8.71-8.81 (m, 1H), 8.97 (dd, 1H).
イソプロピル4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1H−ピラゾロ[3,4−b]ピリジン−3−イル]−5−ピリミジニル(エチル)カルバメート
収量:43mg(理論値の67%)
LC/MS(方法1):Rt=2.97分
MS(EI):m/z=465(M+H)+
1H-NMR (200 MHz, DMSO-d6): δ = 0.96-1.06 (m, 3H), 1.09 (d, 6H), 2.79-2.93 (m, 2H), 4.82 (quin., 1H), 5.80 (s, 2H), 6.25 (br. s, 4H), 7.01-7.14 (m, 2H), 7.15-7.50 (m, 3H), 8.60 (dd, 1H), 9.09 (dd, 1H).
Claims (12)
- 式中、
R1が−NR3C(=O)OR4であり、
R2が水素またはNH2であり、
R3が(C1−C4)−アルキルであり、
R4が(C1−C4)−アルキルである、
請求項1に記載の化合物、またはそれらの塩もしくは水和物。 - 式中、
R1が−NR3C(=O)OR4であり、
R2がNH2であり、
R3がメチルまたはエチルであり、
R4がメチル、エチルまたはイソプロピルである、
請求項1に記載の化合物、またはそれらの塩もしくは水和物。 - 障害の処置のための、請求項1に記載の式(I)の化合物。
- 少なくとも1つの請求項1に記載の式(I)の化合物、および少なくとも1つのさらなる賦形剤を含む、医薬。
- 少なくとも1つの有機硝酸塩またはNO供与体と組み合わせた少なくとも1つの請求項1に記載の式(I)の化合物を含む、医薬。
- 少なくとも1つのサイクリックグアノシン一リン酸(cGMP)の分解を阻害する化合物と組み合わせた少なくとも1つの請求項1に記載の式(I)の化合物を含む、医薬。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10220570A DE10220570A1 (de) | 2002-05-08 | 2002-05-08 | Carbamat-substituierte Pyrazolopyridine |
| PCT/EP2003/004304 WO2003095451A1 (de) | 2002-05-08 | 2003-04-25 | Carbamat-substituierte pyrazolopyridine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005531553A JP2005531553A (ja) | 2005-10-20 |
| JP2005531553A5 JP2005531553A5 (ja) | 2009-12-10 |
| JP4455321B2 true JP4455321B2 (ja) | 2010-04-21 |
Family
ID=29265155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503467A Expired - Lifetime JP4455321B2 (ja) | 2002-05-08 | 2003-04-25 | カルバメート置換ピラゾロピリジン類 |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US7173037B2 (ja) |
| EP (1) | EP1506193B9 (ja) |
| JP (1) | JP4455321B2 (ja) |
| KR (1) | KR101011864B1 (ja) |
| CN (1) | CN1330649C (ja) |
| AR (1) | AR039789A1 (ja) |
| AT (1) | ATE330957T1 (ja) |
| AU (1) | AU2003233061B2 (ja) |
| BE (1) | BE2014C030I2 (ja) |
| BR (1) | BRPI0309855B8 (ja) |
| CA (1) | CA2485143C (ja) |
| CU (1) | CU23453B7 (ja) |
| CY (2) | CY1105579T1 (ja) |
| DE (2) | DE10220570A1 (ja) |
| DK (1) | DK1506193T6 (ja) |
| DO (1) | DOP2003000639A (ja) |
| EC (1) | ECSP045414A (ja) |
| ES (1) | ES2268363T3 (ja) |
| FI (1) | FI1506193T6 (ja) |
| FR (1) | FR14C0032I2 (ja) |
| GT (1) | GT200300101A (ja) |
| HR (1) | HRP20041166B1 (ja) |
| IL (1) | IL164958A (ja) |
| LT (1) | LTC1506193I2 (ja) |
| LU (1) | LU92419I2 (ja) |
| MX (1) | MXPA04011003A (ja) |
| MY (1) | MY136841A (ja) |
| NL (1) | NL300659I2 (ja) |
| NO (3) | NO329105B1 (ja) |
| NZ (1) | NZ536417A (ja) |
| PE (1) | PE20040197A1 (ja) |
| PL (1) | PL214985B1 (ja) |
| PT (1) | PT1506193E (ja) |
| RU (1) | RU2339638C9 (ja) |
| SI (1) | SI1506193T2 (ja) |
| TW (1) | TWI282792B (ja) |
| UA (1) | UA78314C2 (ja) |
| UY (1) | UY27793A1 (ja) |
| WO (1) | WO2003095451A1 (ja) |
| ZA (1) | ZA200408925B (ja) |
Families Citing this family (329)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
| US20060122240A1 (en) * | 2002-11-05 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
| CN1805938B (zh) | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| MXPA05013365A (es) * | 2003-06-20 | 2006-04-05 | Arena Pharm Inc | Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c. |
| TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| DE10351903A1 (de) * | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
| DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
| EP1799210A1 (en) * | 2004-10-05 | 2007-06-27 | Bayer HealthCare AG | A guanylate cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasconstriction |
| NZ589951A (en) * | 2004-12-23 | 2012-11-30 | Arena Pharm Inc | 5HT2C receptor modulator compositions and methods of use |
| DE102005031575A1 (de) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung |
| DE102005031576A1 (de) * | 2005-07-06 | 2007-01-25 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden |
| DE102005047945A1 (de) * | 2005-07-16 | 2007-01-18 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen |
| DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
| DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| DE102006043443A1 (de) * | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102006044696A1 (de) * | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
| DE102006054757A1 (de) * | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
| DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
| DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
| DE102007019691A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
| DE102007019690A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
| BRPI0811581A2 (pt) * | 2007-05-12 | 2014-12-09 | Bayer Schering Pharma Ag | Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos |
| DE102007026392A1 (de) * | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
| DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
| DE102007027799A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
| DE102007035367A1 (de) * | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| DE102007042754A1 (de) * | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
| DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
| DE102007054786A1 (de) | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
| DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
| DE102007061766A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
| DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
| DE102008052013A1 (de) | 2008-10-17 | 2010-04-22 | Bayer Schering Pharma Aktiengesellschaft | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
| DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
| DE102007061764A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
| DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
| DE102008007400A1 (de) | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
| US8822727B2 (en) * | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
| DE102008018675A1 (de) | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung |
| MX2010012228A (es) * | 2008-05-10 | 2010-12-07 | Bayer Schering Pharma Ag | Estimuladores de sgc, activadores de sgc y combinaciones de los mismos para el tratamiento de la deficiencia auditiva. |
| JP2011520997A (ja) * | 2008-05-29 | 2011-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 2−アルコキシ置換ジシアノピリジン類およびそれらの使用 |
| DE102008030207A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
| DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
| DE102008054205A1 (de) * | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
| CA2743864A1 (en) * | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
| DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
| DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
| US20120022028A1 (en) * | 2009-01-17 | 2012-01-26 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction |
| DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
| DE102009012314A1 (de) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
| DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
| DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| US9260424B2 (en) * | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
| DK3415515T3 (da) * | 2009-11-27 | 2020-03-16 | Adverio Pharma Gmbh | Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat |
| UY33040A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pahrma Akitengesellschaft | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |
| EP2513101A1 (de) | 2009-12-14 | 2012-10-24 | Bayer Intellectual Property GmbH | Neue solvate von methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamat |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| BR112012019666A2 (pt) | 2010-02-05 | 2017-06-20 | Bayer Ip Gmbh | estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística |
| ES2635340T3 (es) | 2010-02-27 | 2017-10-03 | Bayer Intellectual Property Gmbh | Ariltriazolonas ligadas a bis-arilo y su uso |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
| ES2549979T3 (es) * | 2010-05-26 | 2015-11-03 | Adverio Pharma Gmbh | El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS) |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| UA107112C2 (uk) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| WO2011153206A1 (en) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
| DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
| CA2803688A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
| DE102011003315A1 (de) | 2011-01-28 | 2012-08-02 | Bayer Schering Pharma Aktiengesellschaft | Annellierte Pyrimindine und Triazine und ihre Verwendung |
| DE102010031149A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Schering Pharma Aktiengesellschaft | Annellierte Pyrimidine und Triazine und ihre Verwendung |
| DE102011007891A1 (de) | 2011-04-21 | 2012-10-25 | Bayer Pharma Aktiengesellschaft | Annellierte 4-Aminopyrimidine und ihre Verwendung |
| EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| JP5940062B2 (ja) | 2010-07-09 | 2016-06-29 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 環縮合4−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用 |
| DE102010031148A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Schering Pharma Ag | Annellierte 4-Aminopyrimidine und ihre Verwendung |
| BR112013000946B1 (pt) | 2010-07-14 | 2020-09-08 | Novartis Ag | Compostos heterocíclicos agonistas de receptor de ip, seus usos, composição e combinação farmacêuticas |
| DE102010031667A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung |
| DE102010031666A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Carbamat-substituierte Diaminopyrimidine und ihre Verwendung |
| DE102010031665A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung |
| EA201390335A1 (ru) | 2010-09-01 | 2013-09-30 | Арена Фармасьютикалз, Инк. | Введение лоркасерина индивидуумам с почечной недостаточностью |
| JP2013539470A (ja) | 2010-09-01 | 2013-10-24 | アリーナ ファーマシューティカルズ, インコーポレイテッド | ロルカセリンと光学活性な酸との塩 |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ht2c 작동제의 변형-방출 투여 형태 |
| KR20130101524A (ko) | 2010-09-01 | 2013-09-13 | 아레나 파마슈티칼스, 인크. | 5-ht2c 아고니스트의 비-흡습성 염 |
| DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
| US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
| CN102485724B (zh) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代噻吩基吡唑并吡啶类化合物及其医药用途 |
| DE102010062544A1 (de) | 2010-12-07 | 2012-06-14 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 1-Benzylcycloalkylcarbonsäuren und ihre Verwendung |
| DE102011006974A1 (de) | 2011-04-07 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte 1-Benzylcycloalkylcarbonsäuren und ihre Verwendung |
| JP5989660B2 (ja) | 2010-12-07 | 2016-09-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換1−ベンジルシクロアルキルカルボン酸およびその使用 |
| US20140171434A1 (en) | 2011-01-11 | 2014-06-19 | Bayer Pharma Aktiengessellschaft | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| DE102011075399A1 (de) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung |
| DE102012200356A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| DE102011007890A1 (de) | 2011-04-21 | 2012-10-25 | Bayer Pharma Aktiengesellschaft | Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung |
| WO2012143510A1 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung |
| DE102012200357A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung |
| DE102011075398A1 (de) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituierte Imidazopyridazine und ihre Verwendung |
| EP2716642B1 (en) | 2011-05-30 | 2016-07-20 | Astellas Pharma Inc. | Imidazopyridine compound |
| AU2012280474A1 (en) | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| DE102012200354A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung |
| DE102011078715A1 (de) | 2011-07-06 | 2013-01-10 | Bayer Pharma AG | Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung |
| CN103906752B (zh) * | 2011-07-06 | 2016-08-24 | 拜耳知识产权有限责任公司 | 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途 |
| AU2012283235A1 (en) | 2011-07-08 | 2014-01-09 | Bayer Intellectual Property Gmbh | Fusion proteins releasing Relaxin and uses thereof |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| DE102012200351A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Pharma Aktiengesellschaft | Substituierte annellierte Pyrimidine und ihre Verwendung |
| BR112014005110A2 (pt) | 2011-09-02 | 2017-04-18 | Bayer Ip Gmbh | pirimidinas aneladas substituídas e utilização das mesmas |
| DE102011082041A1 (de) | 2011-09-02 | 2013-03-07 | Bayer Pharma AG | Substituierte annellierte Pyrimidine und ihre Verwendung |
| HUE053745T2 (hu) | 2011-11-25 | 2021-07-28 | Adverio Pharma Gmbh | Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában |
| CN102491974B (zh) * | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| DE102012200349A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
| DE102012200352A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| EP2802583A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| WO2013105058A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
| US9174985B2 (en) | 2012-01-13 | 2015-11-03 | Novartis Ag | Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists |
| EP2802582A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| AR089698A1 (es) | 2012-01-13 | 2014-09-10 | Novartis Ag | Compuestos heterociclicos antagonistas del receptor ip |
| JP6140738B2 (ja) | 2012-03-06 | 2017-05-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換アザ二環およびその使用 |
| WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
| RU2640416C2 (ru) | 2012-04-16 | 2018-01-09 | Тоа Эйо Лтд. | Бициклическое соединение |
| UA112897C2 (uk) | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| DE102012208530A1 (de) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituierte Piperidinoacetamide und ihre Verwendung |
| PL2875003T3 (pl) | 2012-07-20 | 2017-05-31 | Bayer Pharma Aktiengesellschaft | Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie |
| JP6324956B2 (ja) | 2012-07-20 | 2018-05-16 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換アミノインダン−およびアミノテトラリンカルボン酸ならびにその使用 |
| RU2674670C1 (ru) | 2012-10-09 | 2018-12-12 | Арена Фармасьютикалз, Инк. | Способ коррекции массы тела |
| EP2927231B1 (en) | 2012-11-30 | 2017-09-20 | Astellas Pharma Inc. | Imidazopyridine compounds |
| ES2637719T3 (es) | 2013-02-13 | 2017-10-16 | Novartis Ag | Compuestos heterocíclicos agonistas del receptor IP |
| CA2901636A1 (en) | 2013-02-21 | 2014-08-28 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
| HK1220974A1 (zh) | 2013-03-01 | 2017-05-19 | Bayer Pharma Aktiengesellschaft | 三氟甲基取代的稠合嘧啶类及其用途 |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| WO2014131741A1 (de) | 2013-03-01 | 2014-09-04 | Bayer Pharma Aktiengesellschaft | Benzyl-substituierte pyrazolopyridine und ihre verwendung |
| ES2911276T3 (es) | 2013-03-15 | 2022-05-18 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| EP3004095A1 (de) * | 2013-06-03 | 2016-04-13 | Bayer Pharma Aktiengesellschaft | Triazolopyridine als thrombininhibitoren zur behandlung von thromboembolischen erkrankungen |
| US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
| AP2016008970A0 (en) | 2013-07-10 | 2016-01-31 | Bayer Pharma AG | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof |
| WO2015011086A1 (en) | 2013-07-25 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
| CA2920565A1 (en) * | 2013-08-08 | 2015-02-12 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridine-3-carboxamides and use thereof |
| EP3046912A1 (de) | 2013-09-16 | 2016-07-27 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
| EA201600318A1 (ru) | 2013-10-07 | 2016-09-30 | Байер Фарма Акциенгезельшафт | Циклические тиеноурацилкарбоксамиды и их применение |
| EP3059224B1 (en) | 2013-10-15 | 2019-03-20 | TOA Eiyo Ltd. | 4-aminomethylbenzoic acid derivative |
| CN104327107A (zh) * | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
| CN105813637A (zh) * | 2013-11-01 | 2016-07-27 | 卑尔根技术转移公司 | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 |
| CA2929763A1 (en) | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
| US9751843B2 (en) | 2013-11-08 | 2017-09-05 | Bayer Pharma Aktiengesellschaft | Substituted uracils and use thereof |
| WO2015088885A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP3079700B1 (en) | 2013-12-11 | 2020-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP2016540017A (ja) * | 2013-12-11 | 2016-12-22 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC刺激物質 |
| JP2017503783A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体アルファ2c拮抗薬としての置換されたビピペリジニル誘導体 |
| JP2017501164A (ja) | 2013-12-19 | 2017-01-12 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたピペリジニルテトラヒドロキノリン類 |
| SG11201604978QA (en) | 2013-12-19 | 2016-07-28 | Bayer Pharma AG | Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists |
| CA2934134A1 (en) | 2013-12-19 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| CN106459090A (zh) | 2014-02-19 | 2017-02-22 | 拜耳制药股份公司 | 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶 |
| WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| US20170114049A1 (en) | 2014-04-03 | 2017-04-27 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases |
| CN106458938A (zh) | 2014-04-03 | 2017-02-22 | 拜耳制药股份公司 | 手性2,5‑二取代的环戊烷甲酸衍生物及其用途 |
| AU2014391610B2 (en) | 2014-04-24 | 2018-01-25 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| USRE49575E1 (en) | 2014-08-01 | 2023-07-11 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
| EP3186251A1 (de) | 2014-08-29 | 2017-07-05 | Bayer Pharma Aktiengesellschaft | Substituierte annellierte pyrimidine und ihre verwendung |
| WO2016030354A1 (de) | 2014-08-29 | 2016-03-03 | Bayer Pharma Aktiengesellschaft | Amino-substituierte annellierte pyrimidine und ihre verwendung |
| US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| EP3194382B1 (en) | 2014-09-17 | 2021-09-08 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sgc stimulators |
| US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| ES2712886T3 (es) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| US20170313665A1 (en) | 2014-11-03 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| CN104374861B (zh) * | 2014-11-10 | 2016-03-02 | 广东东阳光药业有限公司 | 一种用hplc分离测定利奥西呱原料药的有关物质的方法 |
| CN104434845B (zh) * | 2014-11-12 | 2017-12-05 | 广东东阳光药业有限公司 | 一种包含利奥西呱的固体药物制剂 |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| WO2016087343A1 (de) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| CN105777743A (zh) * | 2014-12-19 | 2016-07-20 | 奥浦顿(上海)医药科技有限公司 | 一种吡唑并[3,4-b]吡啶类化合物中间体的制备方法和应用 |
| CN104530044B (zh) * | 2014-12-31 | 2016-07-13 | 安徽联创生物医药股份有限公司 | 一种利奥西呱的合成方法 |
| WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
| WO2016113415A1 (en) | 2015-01-16 | 2016-07-21 | Sandoz Ag | Process for the preparation of riociguat essentially free from genotoxic impurities |
| UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
| TN2017000465A1 (en) | 2015-05-06 | 2019-04-12 | Bayer Pharma AG | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
| US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
| EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| LT3325013T (lt) | 2015-07-23 | 2020-11-10 | Bayer Pharma Aktiengesellschaft | Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas |
| WO2017025981A1 (en) * | 2015-08-13 | 2017-02-16 | Msn Laboratories Private Limited | Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof |
| EP3337800B1 (de) | 2015-08-21 | 2019-06-12 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff |
| WO2017081044A1 (en) | 2015-11-13 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
| WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
| CU20180056A7 (es) | 2015-12-10 | 2018-10-04 | Bayer Pharma AG | Derivados de 2-fenil-3-(piperazinometil)imidazo(1,2-a)piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios |
| KR20180094965A (ko) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도 |
| CN105461715B (zh) * | 2015-12-15 | 2017-03-29 | 郑州大明药物科技有限公司 | 一种利奥西呱中间体的合成方法 |
| US10414766B2 (en) * | 2015-12-15 | 2019-09-17 | Alembic Pharmaceuticals Limited | Polymorph of Riociguat and its process for the preparation |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| WO2017121700A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
| WO2017121692A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituierte sulfamide und ihre verwendung |
| WO2017121693A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituierte thiazol- und thiadiazolamide und ihre verwendung |
| WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
| WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
| WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
| WO2017191105A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
| WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| EP3452469A1 (en) | 2016-05-03 | 2019-03-13 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
| EP3452457B1 (en) | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
| AR108265A1 (es) | 2016-05-03 | 2018-08-01 | Bayer Pharma AG | Derivados de feniltriazol sustituidos con amida y usos de estos |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
| EA039753B1 (ru) | 2016-07-07 | 2022-03-10 | Сайклерион Терапьютикс, Инк. | ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC |
| KR102513343B1 (ko) | 2016-07-07 | 2023-03-22 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 인 전구약물 |
| CA3030204A1 (en) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
| IL264955B (en) | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| SG11201902588PA (en) | 2016-09-23 | 2019-05-30 | Bayer Ag | N3-Cyclically Substituted Thienouracils And Use Thereof |
| ES2985316T3 (es) | 2016-10-11 | 2024-11-05 | Bayer Pharma AG | Combinación que contiene el estimulador sGC vericuguat y el antagonista de los receptores de corticoides minerales finerenona |
| US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
| JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| CN107964011A (zh) * | 2016-10-19 | 2018-04-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代吡唑并吡啶类衍生物及其医药用途 |
| US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
| AU2017356887B2 (en) | 2016-11-08 | 2022-06-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| EP3538096B1 (en) | 2016-11-08 | 2024-02-28 | Tisento Therapeutics Inc. | Treatment of cns diseases with sgc stimulators |
| WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| EA202192558A1 (ru) * | 2016-12-14 | 2021-12-07 | Байер Акциенгезельшафт | Замещенные диазагетеробициклические соединения и их применение |
| EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| EP3338764A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| EP3338803A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
| WO2018130226A1 (zh) * | 2017-01-16 | 2018-07-19 | 苏州科睿思制药有限公司 | 利奥西呱的新晶型及其制备方法和用途 |
| SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
| PE20191616A1 (es) | 2017-04-10 | 2019-11-05 | Bayer Ag | N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso |
| TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| CN108690016B (zh) * | 2017-04-11 | 2022-08-12 | 广东东阳光药业有限公司 | 吡唑并吡啶类化合物及其用途 |
| KR102615821B1 (ko) | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| EP3700900A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
| WO2019081303A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
| EP3700899A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| MA50440A (fr) | 2017-10-24 | 2020-09-02 | Bayer Ag | Imidazopyridinamides substituées et leur utilisation |
| WO2019081302A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| CA3079770A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
| US11298367B2 (en) | 2017-10-24 | 2022-04-12 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
| WO2019091847A1 (de) | 2017-11-07 | 2019-05-16 | Bayer Aktiengesellschaft | Substituierte 2,4-dihydro-3h-1,2,4-triazol-3-one und ihre verwendung |
| PE20211391A1 (es) | 2017-12-01 | 2021-07-27 | Bayer Pharma AG | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico |
| JP7337067B2 (ja) * | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC刺激薬 |
| CN111836812A (zh) | 2018-03-07 | 2020-10-27 | 塞科里昂医疗股份有限公司 | sGC刺激剂的晶型 |
| EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| MA52616A (fr) | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| SG11202010679SA (en) | 2018-05-17 | 2020-11-27 | Bayer Ag | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
| CN110511219B (zh) | 2018-05-22 | 2022-06-03 | 年衍药业(珠海)有限公司 | 苯基取代的二氢萘啶类化合物及其用途 |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| TW202019402A (zh) | 2018-07-24 | 2020-06-01 | 德商拜耳廠股份有限公司 | 可口服之修飾釋放藥物劑型 |
| US20210283046A1 (en) | 2018-07-24 | 2021-09-16 | Bayer Aktiengesellschaft | Pharmaceutical dosage form which can be administered orally and has modified release |
| PE20211285A1 (es) | 2018-11-27 | 2021-07-19 | Bayer Ag | Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios |
| EP3887376A1 (en) | 2018-11-28 | 2021-10-06 | Topadur Pharma AG | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| WO2020165031A1 (de) | 2019-02-15 | 2020-08-20 | Bayer Aktiengesellschaft | Substituierte isochinolin-piperidinylmethanon-derivate |
| WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| CA3139209A1 (en) | 2019-05-07 | 2020-11-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| TW202112359A (zh) | 2019-06-07 | 2021-04-01 | 德商拜耳廠股份有限公司 | sGC活化劑於治療眼科疾病之用途 |
| CN120025328A (zh) | 2019-11-06 | 2025-05-23 | 拜耳公司 | 肾上腺素能受体adrac2拮抗剂 |
| WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
| WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス,インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症(PH-HF-pEF)を治療するためのレボシメンダン |
| CA3170507A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
| WO2021172982A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
| US20230130739A1 (en) | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
| WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
| EP3925953A1 (en) * | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
| WO2022057836A1 (zh) * | 2020-09-16 | 2022-03-24 | 南京明德新药研发有限公司 | 苯并脲环衍生物及其制备方法和应用 |
| CA3200103A1 (en) | 2020-11-04 | 2022-05-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
| WO2022122917A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
| CA3204595A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
| EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CN116710439B (zh) | 2020-12-10 | 2026-05-26 | 拜耳公司 | 取代的吡唑并哌啶羧酸 |
| EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| WO2022225902A1 (en) | 2021-04-20 | 2022-10-27 | Cyclerion Therapeutics, Inc. | Treatment of cns diseases with sgc stimulators |
| MX2023012398A (es) | 2021-04-20 | 2024-03-13 | Tisento Therapeutics Inc | Estimuladores de guanilil ciclasa soluble (sgc). |
| WO2022228365A1 (zh) * | 2021-04-27 | 2022-11-03 | 南京明德新药研发有限公司 | 六元杂芳并脲环的衍生物及其应用 |
| WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
| WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
| AU2022429647A1 (en) | 2021-12-29 | 2024-07-04 | Bayer Aktiengesellschaft | Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound |
| TW202342034A (zh) | 2021-12-29 | 2023-11-01 | 德商拜耳廠股份有限公司 | 心肺病症之治療 |
| TW202342035A (zh) | 2021-12-29 | 2023-11-01 | 德商拜耳廠股份有限公司 | 醫藥乾粉吸入配製物 |
| EP4456897A4 (en) | 2021-12-31 | 2025-12-10 | Tenax Therapeutics Inc | ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION |
| CN119300815A (zh) | 2022-06-09 | 2025-01-10 | 拜耳公司 | 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂 |
| CN115947689B (zh) * | 2022-09-23 | 2025-08-29 | 湖南华腾制药有限公司 | 一种连续流微反应器合成利奥西呱中间体的方法 |
| EP4605394A1 (en) | 2022-10-18 | 2025-08-27 | Tisento Therapeutics Inc. | Pyrimidine sgc stimulators |
| EP4605080A1 (en) | 2022-10-18 | 2025-08-27 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
| KR20260083348A (ko) | 2023-09-28 | 2026-06-05 | 바이엘 악티엔게젤샤프트 | 치환된 헤테로시클릭 카르복스아미드 및 그의 용도 |
| CN117924280B (zh) * | 2024-03-20 | 2024-07-12 | 中国人民解放军军事科学院军事医学研究院 | 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途 |
| CN121800783B (zh) * | 2026-03-09 | 2026-06-19 | 四川大学华西医院 | 一种环状嘧啶衍生物、药物组合物及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| ATE431347T1 (de) | 1996-10-14 | 2009-05-15 | Bayer Healthcare Ag | Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen |
| DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| HU227841B1 (en) | 1997-11-12 | 2012-05-02 | Bayer Pharma AG | 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof |
| DE19834045A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| AU2002221827A1 (en) | 2000-11-22 | 2002-06-03 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10057754A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
| DE10057751A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| DE10122894A1 (de) * | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
| DE10132416A1 (de) * | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
| DE10350148B3 (de) | 2003-10-28 | 2005-02-10 | Daimlerchrysler Ag | Baureihe für einen Fahrzeugsitz |
-
2002
- 2002-05-08 DE DE10220570A patent/DE10220570A1/de not_active Withdrawn
-
2003
- 2003-04-25 CN CNB038161605A patent/CN1330649C/zh not_active Expired - Lifetime
- 2003-04-25 PL PL373336A patent/PL214985B1/pl unknown
- 2003-04-25 DE DE50303960T patent/DE50303960D1/de not_active Expired - Lifetime
- 2003-04-25 PT PT03727359T patent/PT1506193E/pt unknown
- 2003-04-25 SI SI200330432T patent/SI1506193T2/sl unknown
- 2003-04-25 NZ NZ536417A patent/NZ536417A/en not_active IP Right Cessation
- 2003-04-25 UA UA20041210078A patent/UA78314C2/uk unknown
- 2003-04-25 MX MXPA04011003A patent/MXPA04011003A/es active IP Right Grant
- 2003-04-25 CA CA2485143A patent/CA2485143C/en not_active Expired - Lifetime
- 2003-04-25 AT AT03727359T patent/ATE330957T1/de active
- 2003-04-25 AU AU2003233061A patent/AU2003233061B2/en active Active
- 2003-04-25 KR KR1020047017877A patent/KR101011864B1/ko not_active Expired - Lifetime
- 2003-04-25 BR BRPI0309855A patent/BRPI0309855B8/pt not_active IP Right Cessation
- 2003-04-25 HR HRP20041166AA patent/HRP20041166B1/hr not_active IP Right Cessation
- 2003-04-25 ES ES03727359T patent/ES2268363T3/es not_active Expired - Lifetime
- 2003-04-25 DK DK03727359.6T patent/DK1506193T6/da active
- 2003-04-25 FI FIEP03727359.6T patent/FI1506193T6/fi active
- 2003-04-25 JP JP2004503467A patent/JP4455321B2/ja not_active Expired - Lifetime
- 2003-04-25 EP EP03727359.6A patent/EP1506193B9/de not_active Expired - Lifetime
- 2003-04-25 RU RU2004136277/04A patent/RU2339638C9/ru active
- 2003-04-25 US US10/513,869 patent/US7173037B2/en active Active
- 2003-04-25 WO PCT/EP2003/004304 patent/WO2003095451A1/de not_active Ceased
- 2003-04-29 DO DO2003000639A patent/DOP2003000639A/es unknown
- 2003-05-05 GT GT200300101A patent/GT200300101A/es unknown
- 2003-05-06 AR ARP030101587A patent/AR039789A1/es active IP Right Grant
- 2003-05-06 MY MYPI20031695A patent/MY136841A/en unknown
- 2003-05-06 UY UY27793A patent/UY27793A1/es not_active IP Right Cessation
- 2003-05-07 TW TW092112381A patent/TWI282792B/zh active
- 2003-05-07 PE PE2003000444A patent/PE20040197A1/es active IP Right Grant
-
2004
- 2004-11-01 IL IL164958A patent/IL164958A/en active Protection Beyond IP Right Term
- 2004-11-04 ZA ZA2004/08925A patent/ZA200408925B/en unknown
- 2004-11-08 EC EC2004005414A patent/ECSP045414A/es unknown
- 2004-11-08 CU CU20040257A patent/CU23453B7/es unknown
- 2004-12-01 NO NO20045277A patent/NO329105B1/no not_active IP Right Cessation
-
2006
- 2006-09-14 CY CY20061101309T patent/CY1105579T1/el unknown
-
2014
- 2014-04-01 NL NL300659C patent/NL300659I2/nl unknown
- 2014-04-02 LU LU92419C patent/LU92419I2/fr unknown
- 2014-04-04 LT LTPA2014018C patent/LTC1506193I2/lt unknown
- 2014-04-11 FR FR14C0032C patent/FR14C0032I2/fr active Active
- 2014-04-25 CY CY2014018C patent/CY2014018I1/el unknown
- 2014-05-12 BE BE2014C030C patent/BE2014C030I2/fr unknown
- 2014-07-18 NO NO2014018C patent/NO2014018I2/no not_active IP Right Cessation
-
2025
- 2025-12-12 NO NO2025058C patent/NO2025058I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003233061B2 (en) | Carbamate-substituted pyrazolopyridines | |
| JP4589720B2 (ja) | 2−(1−ベンジル−1h−ピラゾロ(3,4−b)ピリジン−3−イル)−5−(4−ピリジニル)−4−ピリミジンアミン誘導体およびグアニル酸シクラーゼ刺激因子としてのそれらの使用 | |
| JP4246991B2 (ja) | 新規なピリジン置換ピラゾロピリジン誘導体 | |
| JP4309653B2 (ja) | 新規なスルホンアミド置換ピラゾロピリジン誘導体 | |
| JP2005501034A (ja) | モルホリン架橋のピラゾロピリジン誘導体 | |
| JP2005537274A (ja) | 4−アミノ置換ピリミジン誘導体 | |
| ZA200303887B (en) | Novel pyridine-substituted pyrazolopyridine derivatives. | |
| HK1082247B (en) | Carbamate-substituted pyrazolopyridines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090826 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090826 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091023 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20091023 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20091105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091218 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100119 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100203 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4455321 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140212 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140212 Year of fee payment: 4 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140212 Year of fee payment: 4 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
